PD-L1, Melanoma, TME PD-L1, Melanoma, TME

Process APP

Revert

#10123

RUO

PD-L1, Melanoma, TME

Programmed death-ligand 1 (PD-L1) is a transmembrane protein that binds to the inhibitory receptor programmed death 1 receptor (PD-1), causing a down regulation of immune responses. PD-L1 is typically expressed on normal cells but has been observed in immune cells and tumor cells, see [1], while PD-1 is typically expressed on cytotoxic T-cells and other immune cells. Tumor cells can upregulate PD-L1 expression and avoid being attacked by the body’s immune system, making an interruption of the PD-1/PD-L1 interaction an attractive method for assisting the immune system in destroying tumor cells, see [2].

This APP can be used to determine the proportion of PD-L1 positive cells. It quantifies all cells and classifies PD-L1 positive cells based on brown/DAB positive membrane staining.

RUO

Figure 1

Figure 1

Overview of a single PD-L1 stained TMA core with melanoma tissue.

Figure 2

Figure 2

The same core as in FIGURE 1. The core has been automatically outlined, followed by manual editing to exclude stromal and necrotic tissue.

Figure 3

Figure 3

Region of melanoma tissue after PD-L1 analysis. Red labels show PD-L1positive cells and blue labels show PD-L1 negative cells.

Figure 4

Figure 4

Original image region of a medium-positive core with melanoma tissue

Figure 5

Figure 5

Same region as shown in FIGURE 4 after PD-L1 analysis with labels showing positive (red) and negative (blue) cells.

Show more

Details

Auxiliary APPs

APP: 01 Tumor Detect
The Tumor Detection APP is used for initial tumor region detection and is included with the APP.

Quantitative Output variables

The output variables obtained from this protocol are:

  • Negative Cells: Number of negative cells.
  • PD-L1 Positive Cells: Number of PD-L1 positive cells.
  • Total Cells: Number of total cells.
  • PD-L1 Positive Percentage: Percentage of PD-L1 positive cells relative to total number of cells.

Workflow

Step 1: Use the Tumor Detect APP and/or outline tumor regions manually if necessary.

Step 2: Run the PD-L1 APP. Click the save button to transfer the results to the database.

Methods

A hematoxylin input band is filtered with a median filter and combined with image intensity to smoothen out and mitigate granularity of nuclei. Nuclei are then detected using two different size scales of polynomial blob filters in combination with polynomial local linear filters that delimit the cells. Membranes are detected using two different scales of polynomial local linear filters on a DAB input band. Postprocessing steps grow the nuclei blobs and combine/separate adjacent nuclei appropriately to match the hematoxylin band. The classified PD-L1 positive membrane staining is verified by size, shape and intensity constraints and then applied to the adjacent cells to quantify the number of PD-L1 positive cells.

Staining Protocol

Staining protocols have been developed by Dako and Ventana for the following three assays which have been found to produce comparable results, see [3], and are available from their website(s):

  • Dako 22C3
  • Dako 28-8
  • Ventana SP263

Keywords

PD-L1, PD-1, T-cell, cancer, oncology, IHC, membrane, skin, melanoma, digital pathology, image analysis, B7-H1, hematoxylin

References

USERS
This APP was developed in collaboration with NordiQC.

LITERATURE
1. Zou, W., Chen, L. Inhibitory B7-family molecules in the tumour microenvironment, Nat Rev Immunology 2008, 8, 467-477, DOI.

2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer 2012, 12 (4), 252-264, DOI.

3. Hirsch, F. R., et. al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project, Journal of Thoracic Oncology 2017, 12 (2), 208-222, DOI.

Related APPs

Success
Your message has been successfully sent!